Scancell Holdings PLC (SCLP)
Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
13.00p
Buy
13.50p
-0.13p (-0.98%)
Prices updated at 22 Apr 2026, 16:14 BST
| Prices minimum 15 mins delay
Prices in GBX
Scancell Holdings PLC is a biopharmaceutical company focused on the cancer therapeutics market. The company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2025 | 94.95 |
| 2024 | - |
| 2023 | 90.04 |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
Valuation data table
Year | Price / Sales |
|---|---|
| 2026 | 31.09 |
| 2025 | 20.39 |
| 2024 | - |
| 2023 | 16.26 |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
Price/Forward earnings (YTD)
-
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2025 | -52.59 |
| 2024 | -23.24 |
| 2023 | -38.53 |
| 2022 | -10.86 |
| 2021 | -53.48 |
| 2020 | -56.88 |
| 2019 | -44.70 |
| 2018 | -38.72 |
| 2017 | -40.29 |
| 2016 | -28.82 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2025 | - |
| 2024 | - |
| 2023 | - |
| 2022 | 25.18 |
| 2021 | 5.65 |
| 2020 | 1.15 |
| 2019 | 1.13 |
| 2018 | 1.05 |
| 2017 | 1.08 |
| 2016 | 1.06 |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
